Halozyme Therapeutics annual free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Halozyme Therapeutics Free Cash Flow (FCF) History (HALO)
Halozyme Therapeutics reported $644.6M in free cash flow for fiscal 2025, an increase of 37.62% from the previous fiscal year, with a free cash flow margin of 46.15%.
View full Halozyme Therapeutics company overviewHalozyme Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $644.6M | $176.2M | +37.62% | +46.15% |
| 2024 | 2024-12-31 | $468.4M | $95.1M | +25.47% | +46.13% |
| 2023 | 2023-12-31 | $373.3M | $138.0M | +58.64% | +45.01% |
| 2022 | 2022-12-31 | $235.3M | −$62.7M | −21.04% | +35.65% |
| 2021 | 2021-12-31 | $298.0M | $245.0M | +462.76% | +67.22% |
| 2020 | 2020-12-31 | $53.0M | $142.4M | — | +19.79% |
| 2019 | 2019-12-31 | −$89.5M | −$35.3M | — | −45.65% |
| 2018 | 2018-12-31 | −$54.2M | −$186.9M | — | −35.67% |
| 2017 | 2017-12-31 | $132.7M | $186.2M | — | +41.91% |
| 2016 | 2016-12-31 | −$53.5M | −$14.1M | — | −36.48% |
| 2015 | 2015-12-31 | −$39.4M | $9.4M | — | −29.20% |
| 2014 | 2014-12-31 | −$48.9M | $2.8M | — | −64.89% |
| 2013 | 2013-12-31 | −$51.6M | $14.1M | — | −94.23% |
| 2012 | 2012-12-31 | −$65.7M | −$30.6M | — | −155.21% |
| 2011 | 2011-12-31 | −$35.1M | $10.9M | — | −62.63% |
| 2010 | 2010-12-31 | −$46.0M | −$4.4M | — | −337.87% |
| 2009 | 2009-12-31 | −$41.6M | — | — | −304.35% |
Halozyme Therapeutics quarterly free cash flow
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $236.7M | $138.6M | +141.18% | +49.21% |
| Q1 2026 | 2026-03-31 | $176.3M | $23.1M | +15.05% | +46.81% |
| Q4 2025 | 2025-12-31 | $217.6M | $42.2M | +24.05% | +48.17% |
| Q3 2025 | 2025-09-30 | $175.6M | $61.7M | +54.20% | +49.56% |
| Q2 2025 | 2025-06-30 | $98.1M | $44.9M | +84.45% | +30.13% |
| Q1 2025 | 2025-03-31 | $153.3M | $27.4M | +21.76% | +57.87% |
| Q4 2024 | 2024-12-31 | $175.4M | $75.7M | +75.84% | +58.86% |
| Q3 2024 | 2024-09-30 | $113.9M | −$15.6M | −12.06% | +39.25% |
| Q2 2024 | 2024-06-30 | $53.2M | −$12.0M | −18.41% | +23.00% |
| Q1 2024 | 2024-03-31 | $125.9M | $50.3M | +66.54% | +64.27% |
| Q4 2023 | 2023-12-31 | $99.8M | $19.6M | +24.53% | +43.37% |
| Q3 2023 | 2023-09-30 | $129.5M | $60.8M | +88.65% | +59.93% |
| Q2 2023 | 2023-06-30 | $65.2M | $26.0M | +66.13% | +29.51% |
| Q1 2023 | 2023-03-31 | $75.6M | $28.3M | +59.78% | +46.62% |
| Q4 2022 | 2022-12-31 | $80.1M | −$2.2M | −2.73% | +44.14% |
| Q3 2022 | 2022-09-30 | $68.6M | −$52.6M | −43.40% | +32.84% |
| Q2 2022 | 2022-06-30 | $39.3M | $2.9M | +7.98% | +25.77% |
| Q1 2022 | 2022-03-31 | $47.3M | −$10.7M | −18.47% | +40.34% |
| Q4 2021 | 2021-12-31 | $82.4M | $33.1M | +67.32% | +80.74% |
| Q3 2021 | 2021-09-30 | $121.2M | $115.3M | +1952.18% | +104.67% |
| Q2 2021 | 2021-06-30 | $36.4M | $33.6M | +1208.24% | +26.64% |
| Q1 2021 | 2021-03-31 | $58.0M | $63.0M | — | +65.18% |
| Q4 2020 | 2020-12-31 | $49.2M | $76.5M | — | +40.44% |
| Q3 2020 | 2020-09-30 | $5.9M | $36.6M | — | +9.05% |
| Q2 2020 | 2020-06-30 | $2.8M | $28.9M | — | +5.03% |
| Q1 2020 | 2020-03-31 | −$5.0M | $393,000 | — | −19.56% |
| Q4 2019 | 2019-12-31 | −$27.3M | −$34.7M | — | −50.81% |
| Q3 2019 | 2019-09-30 | −$30.7M | −$11.4M | — | −66.39% |
| Q2 2019 | 2019-06-30 | −$26.2M | −$6.9M | — | −66.81% |
| Q1 2019 | 2019-03-31 | −$5.4M | $17.7M | — | −9.40% |
| Q4 2018 | 2018-12-31 | $7.4M | −$145.0M | −95.15% | +12.27% |
| Q3 2018 | 2018-09-30 | −$19.3M | −$39.4M | — | −75.36% |
| Q2 2018 | 2018-06-30 | −$19.3M | −$2.0M | — | −54.76% |
| Q1 2018 | 2018-03-31 | −$23.0M | −$458,000 | — | −74.55% |
| Q4 2017 | 2017-12-31 | $152.4M | $168.6M | — | +80.39% |
| Q3 2017 | 2017-09-30 | $20.1M | $29.3M | — | +31.54% |
| Q2 2017 | 2017-06-30 | −$17.2M | −$3.2M | — | −51.04% |
| Q1 2017 | 2017-03-31 | −$22.6M | −$8.4M | — | −76.29% |
| Q4 2016 | 2016-12-31 | −$16.2M | $617,000 | — | −41.57% |
| Q3 2016 | 2016-09-30 | −$9.2M | $8.1M | — | −28.79% |
| Q2 2016 | 2016-06-30 | −$14.0M | −$22.7M | — | −42.03% |
| Q1 2016 | 2016-03-31 | −$14.1M | −$153,000 | — | −33.23% |
| Q4 2015 | 2015-12-31 | −$16.8M | −$15.7M | — | −43.15% |
| Q3 2015 | 2015-09-30 | −$17.3M | −$3.8M | — | −54.38% |
| Q2 2015 | 2015-06-30 | $8.7M | $24.8M | — | +26.03% |
| Q1 2015 | 2015-03-31 | −$14.0M | $4.1M | — | −32.87% |
| Q4 2014 | 2014-12-31 | −$1.2M | $15.4M | — | −3.87% |
| Q3 2014 | 2014-09-30 | −$13.6M | −$815,000 | — | −92.80% |
| Q2 2014 | 2014-06-30 | −$16.1M | −$5.1M | — | −87.66% |
| Q1 2014 | 2014-03-31 | −$18.0M | −$6.8M | — | −150.77% |
| Q4 2013 | 2013-12-31 | −$16.6M | $829,929 | — | −132.63% |
| Q3 2013 | 2013-09-30 | −$12.7M | $1.7M | — | −79.55% |
| Q2 2013 | 2013-06-30 | −$11.0M | $3.4M | — | −76.35% |
| Q1 2013 | 2013-03-31 | −$11.3M | $8.1M | — | −95.36% |
| Q4 2012 | 2012-12-31 | −$17.4M | −$3.3M | — | −79.88% |
| Q3 2012 | 2012-09-30 | −$14.5M | −$983,224 | — | −271.18% |
| Q2 2012 | 2012-06-30 | −$14.5M | −$18.2M | — | −186.42% |
| Q1 2012 | 2012-03-31 | −$19.4M | −$8.1M | — | −260.18% |
| Q4 2011 | 2011-12-31 | −$14.1M | — | — | −583.15% |
| Q3 2011 | 2011-09-30 | −$13.5M | −$1.8M | — | −58.77% |
| Q2 2011 | 2011-06-30 | $3.7M | — | — | +16.00% |
| Q1 2011 | 2011-03-31 | −$11.3M | — | — | −149.72% |
| Q3 2010 | 2010-09-30 | −$11.7M | — | — | −343.79% |
Halozyme Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $53.0M to $644.6M, a compound annual growth rate of 64.85%. Halozyme Therapeutics's latest reported quarter, Q2 2026, generated $236.7M in free cash flow, an increase of 141.18% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Halozyme Therapeutics source filings ↗Community posts
Halozyme prices a larger $1.3 billion convertible financing
Halozyme ($HALO) increased its convertible-note offering to $1.3 billion from $1.05 billion and set a 1.50% coupon. The notes mature in 2033 and initially convert at approximately $139.84 per share, a 27.5% premium to the reference share pr ...
Halozyme proposes $1.05 billion convertible refinancing
Halozyme ($HALO) announced plans to sell $1.05 billion of convertible senior notes due in 2033, with an option for initial purchasers to buy a further $150 million. The securities would be senior unsecured obligations paying interest twice ...
